PAR Healthcare Drug Manufacturers - General VIRP.PA

Virbac S.A.

$ 340.50 3.34 %

Founded in 1968 and based in Carros, France, Virbac S.A. is a prominent developer and distributor of a wide array of animal health products and services. The company's global operations extend across France, Europe, Latin America, North America, Asia Pacific, the Middle East, and Africa, catering to both domestic companion animals and commercial livestock. Its extensive portfolio encompasses vaccines, dental hygiene products, reproductive health solutions, dermatological treatments, parasiticides, diagnostic instruments, antibiotics, and aquaculture offerings. Furthermore, Virbac supplies specialized veterinary pharmaceuticals for anesthesia, geriatric care, behavioral management, and injectable micronutrients, alongside pet food and electronic identification systems. These diverse solutions are designed to support veterinarians, agricultural producers, and individual pet owners worldwide.

CEO: Habib Ramdani - https://corporate.virbac.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

Buy

DCF

$ 288.62

Loading data...

VIRP.PA vs S&P500

Loading data...

No data available.

Quick ratio

0.79

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

18.92

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

18.00

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

13.78 %

reflects reasonable profitability, showing good use of equity.

ROIC

9.97 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

7.39

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.26

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

12.63

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

8.05 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
4 indicates moderate financial health
Altman score
4.70 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.24 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.15 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.